# To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

> **NCT04659070** · PHASE3 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 156 (estimated)

## Conditions studied

- Primary Hypercholesterolemia
- Hypertension

## Interventions

- **DRUG:** Experimental : Ezetimibe / Rosuvastatin + Telmisartan
- **DRUG:** Active comparator1 : Ezetimibe / Rosuvastatin
- **DRUG:** Active comparator2 : Telmisartan

## Key facts

- **NCT ID:** NCT04659070
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-15
- **Primary completion:** 2022-05-19
- **Final completion:** 2022-05-19
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659070, "To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04659070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*